Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells

Oncology
Youquan BuFangzhou Song

Abstract

Esophageal cancer ranks among one of the most frequent causes of cancer death in the world. Polo-like kinase 1 (Plk1) is overexpressed in human tumors and has prognostic value in many cancers including esophageal cancer, indicating its potential as a therapeutic target. In this study, we investigated the therapeutic potential of Plk1 in esophageal cancer using the technique of RNA silencing via small interfering RNA (siRNA). Synthetic siRNA duplexes against Plk1 were introduced into 4 esophageal cancer cell lines, which subsequently resulted in a significant inhibition in Plk1 expression in the cells. We found that the targeted depletion of Plk1 caused a dramatic mitotic catastrophe (mitotic cell cycle arrest as well as defects in several mitotic events such as incomplete separation of sister chromatids and failure of cytokinesis) followed by massive apoptotic cell death, and eventually resulted in a significant decrease in growth and viability of all 4 esophageal cancer cell lines studied. In addition, our results also indicated that the mitotic arrest induced by Plk1 depletion is mediated by the inactivation of the cdc2/cyclin B1 complex. Taken together, our study strongly suggests that Plk1 may serve as a potential therapeut...Continue Reading

Citations

Jun 4, 2011·Anti-cancer Drugs·Kristina SpaniolClaudia Lanvers-Kaminsky
Sep 25, 2009·Journal of Experimental & Clinical Cancer Research : CR·Yuan ZhangChun-Zhao Yu
Sep 2, 2010·PloS One·Regina Berretta, Pablo Moscato
Sep 3, 2009·World Journal of Gastroenterology : WJG·Zi-Li HeDe-Wu Zhong
Jul 25, 2012·World Journal of Gastroenterology : WJG·Wei Chuen MokSeng Gee Lim
Mar 26, 2013·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Hee-Jin KimJae-Ryong Kim
Jul 3, 2009·Journal of Cancer Research and Clinical Oncology·Chunling ZhaoLimei Chen
Aug 12, 2009·Cancer Treatment Reviews·Shozo YoshidaHiroshi Kobayashi
Jul 12, 2011·Biotechnology Journal·John C BurnettKatrin Tiemann
Feb 12, 2010·The Journal of International Medical Research·H LuL L Zhu
Apr 20, 2016·Molecular and Cellular Biology·Ion CristóbalJesús García-Foncillas
Jul 17, 2020·Cancer Biotherapy & Radiopharmaceuticals·Ling Chen, Tiejun Zhao
Sep 5, 2020·Journal of Drug Targeting·Ilma ShakeelMd Imtaiyaz Hassan
Apr 7, 2010·Molecular and Cellular Biochemistry·Zhengmei YangFangzhou Song
Sep 27, 2019·Experimental and Therapeutic Medicine·Inga NachreinerMehmet Kemal Tur
Jul 28, 2019·Pharmaceutics·Anna Angela BarbaGaetano Lamberti
Dec 22, 2010·Journal of Cell Science·Anu Kukkonen-MacchiMarko J Kallio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Cycle Control & Proteolysis

Key regulators of cell cycle, including cyclins, cyclin dependent kinase inhibitors, DNA replication factors, are controlled by proteolysis. Discover the latest research on cell cycle control and proteolysis.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis